Expert panel defers decision on Sputnik V Covid-19 vaccine, wants more data

Details of -25°C cold chain plan sought

Sputnik V, Dr Reddy’s Laboratories, DRL, coronavirus, vaccine, covid-19
Earlier in November, a spokesperson for Dr Reddy’s Laboratories (DRL) had said that the vaccine required minus 18 degrees Celsius
Sohini Das Mumbai
2 min read Last Updated : Apr 02 2021 | 2:24 AM IST

Don't want to miss the best from Business Standard?

The wait for Sputnik V in India got a little longer as the expert panel reviewing the application has sought more data on safety, efficacy, and logistics.

A source close to the development said, “No approval was given to Sputnik V on Thursday. Some queries have been asked on safety, efficacy, and logistics, which the firm will have answers to at the next meeting.”

The source quoted earlier confirmed that the queries on logistics were related to the minus 25 degrees Celsius cold chain requirements.

Earlier in November, a spokesperson for Dr Reddy’s Laboratories (DRL) had said that the vaccine required minus 18 degrees Celsius. “Current storage temperature requirement is at minus 18 degrees Celsius. We are working on other storage conditions as well,” the spokesperson had said.

Hyderabad-based DRL has partnered Russian Direct Investment Fund (RDIF) for conducting clinical trials of the vaccine candidate in India. DRL will also be responsible for distribution of the vaccine here. 

DRL had applied for restricted emergency-use authorisation of the Sputnik V in February. The Phase 3 studies ended here on February 21. The firm presented a safety profile from Phase 2 clinical study and interim data from the Phase 3 study. The vaccine underwent a bridge trial in India on 1,600 candidates. 

DRL and RDIF have lined up 250 million doses of the vaccine for Indian citizens (from manufacturing partners) over the next 12 months.

Sources had then indicated that within a few months, a new version of the Sputnik V would be developed that can be stored at a temperature range between 2 and 8 degrees Celsius. However, the new version does not seem ready, as the expert panel has raised queries on a clear logistical plan to handle the minus 25 degrees Celsius cold chain for the vaccine.

A DRL spokesperson said, “We will not be able to provide an official statement now. We have had our meeting with the subject expert committee on Thursday and will await the official outcome.”

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineDr Reddy’s Laboratories

Next Story